The stock has a 36-month beta value of 1.15. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PROK is 44.95M, and at present, short sellers hold a 25.72% of that float. On May 10, 2024, the average trading volume of PROK was 746.49K shares.
PROK) stock’s latest price update
The stock price of ProKidney Corp (NASDAQ: PROK) has jumped by 7.85 compared to previous close of 2.42. Despite this, the company has seen a gain of 21.40% in its stock price over the last five trading days. InvestorPlace reported 2023-11-24 that There are many ways to approach penny stocks, but one that has gained popularity in recent years focuses on stocks in this category that are prime candidates for a “short squeeze.” A typical short squeeze candidate has a high level of short interest, or percentage of outstanding float sold short.
PROK’s Market Performance
ProKidney Corp (PROK) has experienced a 21.40% rise in stock performance for the past week, with a 80.00% rise in the past month, and a 107.14% rise in the past quarter. The volatility ratio for the week is 11.22%, and the volatility levels for the past 30 days are at 20.27% for PROK. The simple moving average for the past 20 days is 13.00% for PROK’s stock, with a -27.08% simple moving average for the past 200 days.
Analysts’ Opinion of PROK
Many brokerage firms have already submitted their reports for PROK stocks, with Morgan Stanley repeating the rating for PROK by listing it as a “Equal-Weight.” The predicted price for PROK in the upcoming period, according to Morgan Stanley is $3 based on the research report published on March 07, 2024 of the current year 2024.
BTIG Research gave a rating of “Buy” to PROK, setting the target price at $16 in the report published on July 25th of the previous year.
PROK Trading at 41.93% from the 50-Day Moving Average
After a stumble in the market that brought PROK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -80.68% of loss for the given period.
Volatility was left at 20.27%, however, over the last 30 days, the volatility rate increased by 11.22%, as shares surge +59.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +66.24% upper at present.
During the last 5 trading sessions, PROK rose by +21.40%, which changed the moving average for the period of 200-days by -77.32% in comparison to the 20-day moving average, which settled at $2.36. In addition, ProKidney Corp saw 46.63% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PROK starting from Weber Darin J., who sale 16,438 shares at the price of $2.51 back on Apr 22 ’24. After this action, Weber Darin J. now owns 155,194 shares of ProKidney Corp, valued at $41,315 using the latest closing price.
Weber Darin J., the SVP of Regulatory Development of ProKidney Corp, sale 800 shares at $2.54 during a trade that took place back on Apr 18 ’24, which means that Weber Darin J. is holding 171,632 shares at $2,028 based on the most recent closing price.
Stock Fundamentals for PROK
The total capital return value is set at -0.34.
Based on ProKidney Corp (PROK), the company’s capital structure generated -0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -20.41. The debt to equity ratio resting at -0.0. The interest coverage ratio of the stock is -16874.88.
Currently, EBITDA for the company is -148.35 million with net debt to EBITDA at 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.94.
Conclusion
To sum up, ProKidney Corp (PROK) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
